CLEC1B and hepatocellular carcinoma: Fast HCCs with CLEC2 lower than median levels had a median survival of 13 months versus 27 months (upregulated CLEC2 and aggressive signature), 44 months (downregulated CLEC2 without aggressive signature) and 48 months (upregulated CLEC2 and slow HCC) (P<0.0001) (Supplementary Figure 2A).